Drug Trial Radar · NCT00190411
Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type
Last checked: Nov 19, 2026Latest source record: Jan 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Oct 2003
Primary completion
Apr 2011
Study completion Apr 2011
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aventis Pharmaceuticals
- First posted
- Sep 19, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ehlers-Danlos syndrome vascular type (EDS-IV) is caused by a genetic defect of collagen type III. Patient die (median 40 yrs) of vascular complications. There is no treatment. We showed that arteries are thin and overloaded in this patients. We test the protective effect of celiprolol on cardiovascular events in a 5 years, randomized, PROBE design
Conditions
- EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT
- CHROMOSOME 2q31.2 DELETION SYNDROME
Interventions
celiprololDrug
celiprolol
ControlDrug
Untreated controls excluding betablockers
Primary outcomes
What the sponsor says the trial is designed to measure.
- reduction in the rate of major cardiovascular events in the treated group during a 5 years follow-upTime frame: during de study
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.